Optiver Holding
VRDN icon

Optiver Holding’s Viridian Therapeutics VRDN Stock Holding History

Optiver Holding’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.96K Buy
542
+324
+149% +$5.22K ﹤0.01% 1749
2026
Q1 		$4.26K Sell
218
-76
-26% -$2.26K ﹤0.01% 1489
2025
Q4 		$9.15K Sell
294
-282
-49% -$7.73K ﹤0.01% 1163
2025
Q3 		$12.4K Buy
+576
New +$10.4K ﹤0.01% 1167

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Optiver Holding's VRDN Position: Q2 2026 in Review

Optiver Holding increased its Viridian Therapeutics (VRDN) stake by 149% in Q2 2026, buying an estimated $5.22K and bringing the position to 542 shares worth $9.96K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Optiver Holding first reported a position in VRDN in Q3 2025 and has held it in 4 quarters since. The position peaked at $12.4K in Q3 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Optiver Holding held 542 shares of Viridian Therapeutics worth $9.96K as of Q2 2026.
  • Optiver Holding bought 324 Viridian Therapeutics shares in Q2 2026, an estimated $5.22K.
  • Viridian Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1749 holding.
  • Optiver Holding first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Viridian Therapeutics position peaked at $12.4K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.